BRPI0409633A - derivado de quinazolina, composição farmacêutica, e processo para a preparação do derivado de quinazolina - Google Patents

derivado de quinazolina, composição farmacêutica, e processo para a preparação do derivado de quinazolina

Info

Publication number
BRPI0409633A
BRPI0409633A BRPI0409633-9A BRPI0409633A BRPI0409633A BR PI0409633 A BRPI0409633 A BR PI0409633A BR PI0409633 A BRPI0409633 A BR PI0409633A BR PI0409633 A BRPI0409633 A BR PI0409633A
Authority
BR
Brazil
Prior art keywords
quinazoline derivative
preparing
pharmaceutical composition
derivative
quinazoline
Prior art date
Application number
BRPI0409633-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert Hugh Bradbury
Jason Grant Kettle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0409633A publication Critical patent/BRPI0409633A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0409633-9A 2003-04-22 2004-04-20 derivado de quinazolina, composição farmacêutica, e processo para a preparação do derivado de quinazolina BRPI0409633A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0309009.9A GB0309009D0 (en) 2003-04-22 2003-04-22 Quinazoline derivatives
PCT/GB2004/001713 WO2004093880A1 (en) 2003-04-22 2004-04-20 4-anilino-quinazoline derivatives as antiproliferative agents

Publications (1)

Publication Number Publication Date
BRPI0409633A true BRPI0409633A (pt) 2006-04-25

Family

ID=9957022

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409633-9A BRPI0409633A (pt) 2003-04-22 2004-04-20 derivado de quinazolina, composição farmacêutica, e processo para a preparação do derivado de quinazolina

Country Status (17)

Country Link
US (1) US20070149546A1 (enExample)
EP (1) EP1631292B1 (enExample)
JP (1) JP2006524218A (enExample)
KR (1) KR20060006821A (enExample)
CN (1) CN100406453C (enExample)
AT (1) ATE438402T1 (enExample)
AU (1) AU2004231349A1 (enExample)
BR (1) BRPI0409633A (enExample)
CA (1) CA2526897A1 (enExample)
DE (1) DE602004022404D1 (enExample)
ES (1) ES2329576T3 (enExample)
GB (1) GB0309009D0 (enExample)
MX (1) MXPA05011332A (enExample)
NO (1) NO20054856L (enExample)
NZ (1) NZ543015A (enExample)
WO (1) WO2004093880A1 (enExample)
ZA (1) ZA200508525B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
ES2320980T3 (es) * 2001-11-03 2009-06-01 Astrazeneca Ab Derivados de quinazolina como agentes antitumorales.
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20070021429A1 (en) * 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
MXPA05012839A (es) * 2003-05-27 2006-05-17 Pfizer Prod Inc Quinazolinas y pirido[3,4-d] pirimidinas como inhibidores de receptores tirosina quinasa.
WO2005026156A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
JP2007505873A (ja) * 2003-09-16 2007-03-15 アストラゼネカ アクチボラグ チロシンキナーゼ阻害剤としてのキナゾリン誘導体
SI1667991T1 (sl) 2003-09-16 2008-10-31 Astrazeneca Ab Kinazolinski derivati kot inhibitorji tirozin kinaze
CA2539049A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
US7632840B2 (en) 2004-02-03 2009-12-15 Astrazeneca Ab Quinazoline compounds for the treatment of hyperproliferative disorders
CN1993349A (zh) * 2004-06-04 2007-07-04 阿斯利康(瑞典)有限公司 作为erbb受体酪氨酸激酶的喹唑啉衍生物
ATE501148T1 (de) * 2004-12-14 2011-03-15 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
GB0427917D0 (en) * 2004-12-21 2005-01-26 Astrazeneca Ab Chemical compounds
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
JP2009508917A (ja) * 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 抗癌剤としてのキナゾリン誘導体
US7820683B2 (en) * 2005-09-20 2010-10-26 Astrazeneca Ab 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
WO2007063293A1 (en) * 2005-12-02 2007-06-07 Astrazeneca Ab Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase
WO2007063291A1 (en) * 2005-12-02 2007-06-07 Astrazeneca Ab 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
SG174774A1 (en) 2006-09-11 2011-10-28 Curis Inc Quinazoline based egfr inhibitors containing a zinc binding moiety
KR101129868B1 (ko) * 2006-10-04 2012-04-12 화이자 프로덕츠 인코포레이티드 칼슘 수용체 길항제로서의 피리도[4,3-d]피리미딘-4(3H)-온 유도체
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JP5377332B2 (ja) 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
US8080558B2 (en) 2007-10-29 2011-12-20 Natco Pharma Limited 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent
BRPI0907916A2 (pt) 2008-02-07 2015-07-28 Boehringer Ingelheim Int Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
AU2009247782C1 (en) 2008-05-13 2013-09-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
JP2012511961A (ja) * 2008-12-11 2012-05-31 プロテウス バイオメディカル インコーポレイテッド 携帯用内臓電気記録システムを用いた消化管機能の判断およびそれを用いた方法
CN115260164B (zh) * 2021-05-01 2024-03-26 杭州星鳌生物科技有限公司 新型4(3h)-喹唑啉酮类似物的制备方法、结构组成及其在抗肿瘤药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
US4921863A (en) * 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
TW321649B (enExample) * 1994-11-12 1997-12-01 Zeneca Ltd
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9702049B1 (pt) * 1996-01-31 2010-08-10 sistema distribuidor contendo dois compartimentos para a dosagem simultánea de duas composições aquosas.
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
DE19651439A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Polymerisierbare Biaryle, Verfahren zur Herstellung und deren Verwendung
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
WO2000051991A1 (en) * 1999-02-27 2000-09-08 Boehringer Ingelheim Pharma Kg 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
EP1396488A1 (en) * 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
ES2320980T3 (es) * 2001-11-03 2009-06-01 Astrazeneca Ab Derivados de quinazolina como agentes antitumorales.
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
EP1660479A1 (en) * 2003-07-29 2006-05-31 Astrazeneca AB Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
SI1667991T1 (sl) * 2003-09-16 2008-10-31 Astrazeneca Ab Kinazolinski derivati kot inhibitorji tirozin kinaze
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
CA2539049A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
JP2007505873A (ja) * 2003-09-16 2007-03-15 アストラゼネカ アクチボラグ チロシンキナーゼ阻害剤としてのキナゾリン誘導体
WO2005028470A1 (en) * 2003-09-19 2005-03-31 Astrazeneca Ab Quinazoline derivatives
AU2004276055A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
US7632840B2 (en) * 2004-02-03 2009-12-15 Astrazeneca Ab Quinazoline compounds for the treatment of hyperproliferative disorders
CN1993349A (zh) * 2004-06-04 2007-07-04 阿斯利康(瑞典)有限公司 作为erbb受体酪氨酸激酶的喹唑啉衍生物

Also Published As

Publication number Publication date
KR20060006821A (ko) 2006-01-19
ATE438402T1 (de) 2009-08-15
GB0309009D0 (en) 2003-05-28
HK1087632A1 (en) 2006-10-20
NO20054856L (no) 2005-11-21
MXPA05011332A (es) 2005-11-28
JP2006524218A (ja) 2006-10-26
EP1631292B1 (en) 2009-08-05
NO20054856D0 (no) 2005-10-20
US20070149546A1 (en) 2007-06-28
NZ543015A (en) 2008-01-31
DE602004022404D1 (de) 2009-09-17
ZA200508525B (en) 2007-04-25
CN1809360A (zh) 2006-07-26
CA2526897A1 (en) 2004-11-04
WO2004093880A1 (en) 2004-11-04
CN100406453C (zh) 2008-07-30
EP1631292A1 (en) 2006-03-08
ES2329576T3 (es) 2009-11-27
AU2004231349A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
BRPI0409633A (pt) derivado de quinazolina, composição farmacêutica, e processo para a preparação do derivado de quinazolina
BRPI0414486A (pt) derivado de quinazolina, composição farmacêutica, e, processo para a preparação de um derivado de quinazolina
BRPI0414447A (pt) derivado de quinazolina, composição farmacêutica, e, processo para a preparação de um derivado de quinazolina
BRPI0416479A (pt) derivado quinazolina, composição farmacêutica, e, processo para a preparação de um derivado de quinazolina
BRPI0414772A (pt) derivado de quinazolina, composto, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, método para produzir um efeito anti-proliferativo em um animal de sangue quente
BR0308670A (pt) Derivado de quinazolina ou um sal deste farmaceuticamente aceitável, processo para a preparação do mesmo, composição farmacêutica, uso do dito derivado ou de seu sal, método para produzir um efeito anti-proliferativo em um animal de sangue quente em necessidade de tal tratamento, e, composto ou um sal deste.
BRPI0415398A (pt) composto, composição farmacêutica, processo para a preparação da mesma, uso de um composto, método de tratamento de cáncer, e, processo para preparação de um composto
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
BR0312443A (pt) Processo para preparação de pirimidinas substituìdas e derivados de pirimidina como inibidores de cinases protéicas
BRPI0414532A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, método para produzir um efeito anti-proliferativo em um animal de sangue quente
BR0212983A (pt) Composto, uso do composto, e, intermediários de sìntese
CR10381A (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
BRPI0415760A (pt) derivados de benzimidazolila
MA28685B1 (fr) Derives de la quinazolinone, antagonistes de la vanilloide
DE602004018637D1 (de) A2a-adenosinrezeptorantagonisten
BRPI0820779B8 (pt) compostos derivados de 4-amino-pirimidina, composição farmacêutica, uso e processo para preparação dos referidos compostos
BRPI0518607A2 (pt) derivados de pirrol tendo atividade antagonista de receptor crth2
BR0307461A (pt) Derivados de quinazolinona e seu uso como agonistas de cb
BRPI0407282A (pt) Processo para preparação de inibidores de pirrolotriazina cinase
BR0317708A (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0411209A (pt) uso de derivados isoindolinona como inseticidas
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
BRPI0512677A2 (pt) derivados de quinazolina
ATE438641T1 (de) Chinazolinderivate als inhibitoren von egf und/oder erbb2-rezeptortyrosinkinase

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]